Ascend GmbH
2 products tracked · names used in filings: Ascend GmbH
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 28 Aug 2026🇪🇺 EU approval (EC decision)
Denosumab Ascend (denosumab) approved in the EU
Marketing authorisation to Ascend GmbH; Biosimilar, Additional monitoring · source
Thu 25 Jun 2026🇪🇺 CHMP positive opinion
Denosumab Ascend (denosumab): CHMP positive opinion
Ascend GmbH; Biosimilar, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Teriparatide Ascend teriparatide | Application withdrawn | |
| 🇪🇺 | Denosumab Ascend denosumab | Authorised | 2026-08-28 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.